Clinical Trials | June 26, 2024
Imfinzi improved event-free survival and overall survival for bladder cancer
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Subscribe To Our Newsletter & Stay Updated
